In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Chronic heart failure in liver transplant recipients: etiology, frequency, management.

Session Poster Session 2

Speaker Elena Kosmacheva

Event : Heart Failure 2018

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Comorbidities
  • Session type : Poster Session

Authors : A Babich (Krasnodar,RU), H Kosmacheva (Krasnodar,RU)

Authors:
A Babich1 , H Kosmacheva1 , 1the Scientific Research Institute-Regional Clinical Hospital 1 - Krasnodar - Russian Federation ,

Citation:

Background: Cardiovascular diseases are among the most frequent causes of patient death after liver transplantation. Due to recent improvements in survival of liver transplant, there is only few data available analyzing the prevalence and management of chronic heart failure (CHF) in liver recipients.

Purpose: The aim of this retrospective clinical study was to estimate the etiology, frequency and management of chronic heart failure before and after liver transplantation. A total of 115 patients who had undergone successful liver transplantation between 2010 and 2016 at the Scientific Research Institute-Regional Clinical Hospital ?1 were studied.

Results: Mean age was 53 ± 13 years and 66 (57.4 %) were men. Chronic heart failure was verified in 20.9% of patients before liver transplantation, among them NYHA class I - 37.5%, NYHA class II- 50%, NYHA class III - 12.5%. Chronic heart failure was considered to develop due to arterial hypertension in 58.3% of patients,  due to coronary heart disease (CHD) in 37.5%, among them six patients had a combination of CHD and arterial hypertension. One case of anteroseptal myocardial infarction (CHF - NYHA class II), 3 new cases of CHF were registered as a complication of arterial hypertension 6 months after liver transplantation. Over 1 year, we observed elevation of new-onset CHF (13%) compared with preoperative, among them NYHA class I had 63.3%, NYHA class II - 36.4% (arterial hypertension and CHF - 90.9%, coronary heart disease and CHF - 9.1%).
Beta-blockers were administrated in 75%, among them 88.9% received nonselective agents - propranolol, 11.1% - bisoprolol before liver transplantation. 24 patients without cardiac pathology and CHF were assigned to propranolol, which is probably associated with portal hypertension in patients before liver transplantation. Retrospective analysis revealed that only 7.1% of recipients with CHF received beta-blockers after 6 months and 7.7% after one year transplantation. ACE inhibitors were received in 16.7% of patients before surgery, after 6 months and after one year - 3.6% and 10.3%, respectively.

Conclusions. The development of chronic heart failure arises after transplantation. We suggest that it is vitally important to manage transplant-related CHF effectively by paying our physicians’ attention to administration of ACE inhibitors and beta-blockers.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are